Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Barclays PLC

Barclays PLC raised its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 139.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 222,919 shares of the company’s stock after buying an additional 129,944 shares during the quarter. Barclays PLC’s holdings in Verve Therapeutics were worth $1,079,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Creative Planning purchased a new stake in Verve Therapeutics in the 3rd quarter worth $50,000. PFG Investments LLC purchased a new stake in shares of Verve Therapeutics during the third quarter worth $53,000. Erste Asset Management GmbH purchased a new stake in shares of Verve Therapeutics during the third quarter worth $56,000. Daiwa Securities Group Inc. grew its holdings in shares of Verve Therapeutics by 89.8% during the second quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock worth $59,000 after buying an additional 5,723 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. grew its holdings in shares of Verve Therapeutics by 13.5% during the second quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock worth $73,000 after buying an additional 1,778 shares in the last quarter. 97.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on VERV shares. Royal Bank of Canada dropped their target price on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. HC Wainwright dropped their target price on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group upped their target price on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Verve Therapeutics Price Performance

NASDAQ VERV opened at $5.54 on Tuesday. The firm’s 50-day moving average is $5.83 and its two-hundred day moving average is $5.68. Verve Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $19.34. The stock has a market capitalization of $469.04 million, a P/E ratio of -2.25 and a beta of 1.71.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.11. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The company had revenue of $6.87 million for the quarter, compared to analysts’ expectations of $2.75 million. During the same quarter in the prior year, the company posted ($0.72) earnings per share. Verve Therapeutics’s revenue for the quarter was up 120.2% compared to the same quarter last year. As a group, analysts anticipate that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.